GLP 1 therapies have changed the way obesity treatment is being understood.
What began as a breakthrough in metabolic care has now created a new challenge for clinical development: capacity.
As more GLP 1 and next generation obesity therapies move through the pipeline, sponsors will need more than promising science. They will need the right sites, the right patient populations, stronger feasibility signals and faster operational execution.
The future of obesity research will not only depend on drug innovation. It will also depend on whether clinical trial infrastructure can keep pace with the scale of demand.
Read the full blog here: https://kitsa.ai/blog/glp1-obesity-clinical-trial-capacity
#ClinicalTrials #GLP1 #ObesityResearch #ClinicalResearch #DrugDevelopment #TrialIntelligence #HealthcareInnovation #LifeSciences #PatientRecruitment #Kitsa
